A unique cell surface antigen identifying lymphoid malignancies of B cell origin

The Journal of Clinical Investigation
L M NadlerP Stashenko

Abstract

A monoclonal antibody (anti-B1) specific for a unique B cell surface differentiation antigen was used to characterize the malignant cells from patients with leukemias or lymphomas. All tumor cells from patients with lymphomas or chronic lymphocytic leukemias, bearing either monoclonal kappa lambda light chain, expressed the B1 antigen. In contrast, tumor cells from T cell leukemias and lymphomas or acute myeloblastic leukemia were unreactive. Approximately 50% of acute lymphoblastic leukemias (ALL) of non-T origin and 50% of chronic myelocytic leukemia in blast crisis were also anti-B1 reactive. moreover, 21 of 28 patients with the common ALL antigen (CALLA) positive form of ALL were anti-B1 positive, whereas 0 of 13 patients with CALLA negative ALL were reactive. These observations demonstrate that an antigen present on normal B cells is expressed on the vast majority of B cell lymphomas and on approximately 75% of CALLA positive ALL, suggesting that these tumors may share a common B cell lineage.

References

Dec 1, 1979·The Journal of Experimental Medicine·E L ReinherzS F Schlossman
Nov 1, 1978·The Journal of Experimental Medicine·R L EvansS F Schlossman
Apr 20, 1978·The New England Journal of Medicine·L B VoglerM D Cooper
Aug 1, 1979·The Journal of Clinical Investigation·E L ReinherzS F Schlossman
Aug 1, 1978·Cancer·J C Brouet, M Seligmann
Apr 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·S F SchlossmanJ L Strominger
Jul 1, 1972·The Journal of Experimental Medicine·H B Dickler, H G Kunkel
Nov 23, 1974·Lancet·S E Salmon, M Seligmann
Aug 10, 1972·The New England Journal of Medicine·A C Aisenberg, K J Bloch
Dec 22, 1971·Nature: New Biology·S FrölandP Berdal
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·E L ReinherzS F Schlossman
Jan 1, 1980·Cancer Chemotherapy and Pharmacology·L M NadlerS F Schlossman
Apr 1, 1980·Cell·E L Reinherz, S F Schlossman

❮ Previous
Next ❯

Citations

Jul 31, 2001·International Journal of Cancer. Journal International Du Cancer·S A KostelnyG J Weiner
Jan 1, 1986·Virchows Archiv. A, Pathological Anatomy and Histopathology·K GeboesR Kerremans
Jul 1, 1983·Journal of Clinical Immunology·G B Melink, T W LeBien
Apr 1, 1981·Journal of Clinical Immunology·M D Cooper
Dec 1, 1981·In Vitro·R H Kennett
Sep 28, 2005·Cancer Immunology, Immunotherapy : CII·Bruce D Cheson
Sep 12, 2007·Cell and Tissue Research·Karl-Henrik GrinnemoMatthias Corbascio
Jan 1, 1983·Pharmacology & Therapeutics·W E Magee, S S Ristow
Oct 28, 1986·Biochimica Et Biophysica Acta·C L Reading, Y Takaue
Jul 28, 1989·Biochimica Et Biophysica Acta·A PedrazziniL M Nadler
Oct 1, 2009·Expert Reviews in Molecular Medicine·John C Morris, Thomas A Waldmann
Aug 9, 2008·The New England Journal of Medicine·Bruce D Cheson, John P Leonard
Jun 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·P StashenkoS F Schlossman
Feb 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·A E FrankelL A Herzenberg
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·S J KorsmeyerT A Waldmann
Nov 21, 1995·Proceedings of the National Academy of Sciences of the United States of America·T KobataC Morimoto
Sep 1, 1981·The Journal of Experimental Medicine·A K BhanS F Schlossman
Jan 1, 1984·The Journal of Experimental Medicine·P AmanG Klein
Mar 17, 2006·Applied Immunohistochemistry & Molecular Morphology : AIMM·Rania M SeliemRobert P Hasserjian
Mar 1, 1989·The British Journal of Ophthalmology·K GeboesL Missotten
Aug 1, 1982·The Journal of Clinical Investigation·L M NadlerS F Schlossman
Apr 1, 1984·The Journal of Clinical Investigation·K HaE W Gelfand
Nov 1, 1984·The Journal of Clinical Investigation·R FoaF Lauria
Mar 1, 1985·The Journal of Clinical Investigation·C MorimotoS F Schlossman
Aug 27, 2003·Gan to kagaku ryoho. Cancer & chemotherapy·Rumiko OkamotoTsuneo Sasaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.